Systematic Review Compares Oxytocin Alternatives for Preventing Postpartum Hemorrhage

Globally, postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality, often defined as blood loss exceeding 500 mL after vaginal birth or 1000 mL after caesarean section. While oxytocin is the standard first-line uterotonic for PPH prevention, its efficacy can be limited by heat stability issues, cost, and potential for uterine atony in some cases. This comprehensive systematic review and meta-analysis aimed to evaluate the comparative effectiveness and safety of various oxytocin alternatives for PPH prevention in both vaginal and caesarean births.

The meta-analysis revealed significant findings regarding the efficacy of oxytocin alternatives. Carbetocin, a long-acting oxytocin analogue, demonstrated superiority over oxytocin, reducing the incidence of PPH by 28% (Relative Risk [RR] 0.72, 95% CI 0.65-0.80, p<0.001) in women undergoing caesarean sections, with comparable adverse effect profiles. Misoprostol was found to be non-inferior to oxytocin in preventing PPH in vaginal births, showing a 15% reduction in severe PPH (blood loss > 1000 mL) compared to placebo (p=0.003), though associated with a higher incidence of shivering and fever. The most impactful finding was that carbetocin significantly reduced the need for additional uterotonics by 35% (RR 0.65, 95% CI 0.58-0.73, p<0.001) and blood transfusions by 22% (RR 0.78, 95% CI 0.69-0.88, p<0.001) compared to oxytocin in caesarean deliveries. Tranexamic acid, when administered adjunctively with a uterotonic, further reduced blood loss by an average of 180 mL (95% CI -210 to -150 mL, p<0.001) and the risk of PPH by 19% (RR 0.81, 95% CI 0.74-0.89, p<0.001) across both delivery types.